SABCS

Kisqali Plus Endocrine Therapy Improves Survival in HR+/HER2– Breast Cancer

December 6th 2023, 4:00pm

Article

Patients with HR-positive HER2-negative advanced breast cancer, including elderly patients, derived a progression-free and overall survival benefit with Kisqali plus endocrine therapy compared with placebo plus endocrine therapy.

Enhertu May Further Improve Survival Versus Xeloda Regimens in HER2-Positive Breast Cancer

December 24th 2022, 6:00pm

Article

Recent study results showed that patients with advanced HER2-positive breast cancer lived longer without disease progression when treated with Enhertu compared to when treated with Xeloda.

Lumpectomy for Multiple Ipsilateral Breast Cancer May Still Fend Against Recurrence at 5 Years Versus Mastectomy

December 16th 2022, 8:00pm

Article

Women with multiple ipsilateral breast cancer may have similar recurrence-free outcomes with a lumpectomy as one might encounter with a mastectomy, opening the door for more surgical treatment options for these patients.

Cognitive Ability May Worsen More With Chemotherapy Plus Endocrine Therapy Versus Endocrine Therapy Alone for Breast Cancer

December 8th 2022, 10:00pm

Article

Patients with breast cancer, regardless of their menopausal status, may face worse cognitive ability with chemotherapy and endocrine therapy, although this may return to its pretreatment level after 36 months.

Tumor Test May Predict Which Patients With HR-Positive Breast Cancer Will Benefit From Ovarian Suppression

December 7th 2022, 10:00pm

Article

Recent research sought to determine which patients with HR-positive breast cancer can benefit by adding ovarian function suppression to their adjuvant regimens, and which patients can skip it.

Keytruda/Chemo Combo Is ‘Great News’ for Patients With TNBC, ‘But We Need Much More’

January 6th 2022, 2:00pm

Article

An expert discusses improvements in survival outcomes for patients with triple-negative breast cancer who received Keytruda plus chemotherapy — now considered the standard of care — but urges that more researched is always needed for this patient population.

Aromatase Inhibitors Reduce Recurrence Risk, But Not Death Rates, in Premenopausal Patients With Breast Cancer

January 5th 2022, 8:15pm

Article

Premenopausal women with ER-positive breast cancer experienced a decreased rate of recurrence when given an aromatase inhibitor, compared with those given tamoxifen. However, more research is still needed, an expert said.

Novel Drug Combo Induces Encouraging Results in Patients With Heavily Pretreated Breast Cancer

January 3rd 2022, 10:00pm

Article

The use of Faslodex plus the investigational drug samuraciclib was considered safe in individuals with heavily pretreated hormone receptor-positive breast cancer.

Second-Line Enhertu May Be ‘Standard of Care’ for Patients with HER2-Positive Metastatic Breast Cancer

December 28th 2021, 4:00pm

Article

The use of Enhertu may also be beneficial across HER2-positive metastatic breast cancer subgroups including patients with and without brain metastases.

Study Results Champion Keytruda/Chemo as ‘New Standard of Care’ in TNBC Subset

December 27th 2021, 10:00pm

Article

The combination of Keytruda and chemotherapy improved survival rates in patients with PD-L1—positive metastatic triple-negative breast cancer.